Jason C. Chandler

3.6k total citations
41 papers, 1.1k citations indexed

About

Jason C. Chandler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Jason C. Chandler has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Genetics. Recurrent topics in Jason C. Chandler's work include Cancer Immunotherapy and Biomarkers (13 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (9 papers). Jason C. Chandler is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (9 papers). Jason C. Chandler collaborates with scholars based in United States, United Kingdom and Germany. Jason C. Chandler's co-authors include David R. Spigel, James L. Gulley, Anja von Heydebreck, Karen Kelly, Nicholas Iannotti, David Waterhouse, Ding Wang, Kevin M. Chin, Robert M. Jotte and Arun Rajan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jason C. Chandler

39 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason C. Chandler United States	14	742	453	246	186	157	41	1.1k
Sunil Babu United States	16	581 0.8×	304 0.7×	441 1.8×	249 1.3×	267 1.7×	38	1.2k
Mark Cornfeld United States	11	497 0.7×	151 0.3×	157 0.6×	294 1.6×	127 0.8×	33	838
Juliana Di Iulio Australia	16	645 0.9×	223 0.5×	103 0.4×	318 1.7×	130 0.8×	34	1.1k
Cécile Charpy France	13	661 0.9×	262 0.6×	357 1.5×	209 1.1×	30 0.2×	29	1.2k
Junning Cao China	16	553 0.7×	213 0.5×	140 0.6×	136 0.7×	43 0.3×	90	907
H.‐G. Mergenthaler Germany	12	543 0.7×	212 0.5×	68 0.3×	111 0.6×	95 0.6×	33	903
Binglin Yue United States	16	320 0.4×	335 0.7×	64 0.3×	194 1.0×	61 0.4×	41	857
Suthee Rapisuwon United States	11	683 0.9×	158 0.3×	246 1.0×	329 1.8×	43 0.3×	30	997
Roel J.W. van Kampen Netherlands	13	562 0.8×	283 0.6×	55 0.2×	118 0.6×	149 0.9×	18	891
Paula G. O’Connor United States	13	576 0.8×	419 0.9×	54 0.2×	178 1.0×	52 0.3×	21	821

Countries citing papers authored by Jason C. Chandler

Since Specialization

Citations

This map shows the geographic impact of Jason C. Chandler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason C. Chandler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason C. Chandler more than expected).

Fields of papers citing papers by Jason C. Chandler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason C. Chandler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason C. Chandler. The network helps show where Jason C. Chandler may publish in the future.

Co-authorship network of co-authors of Jason C. Chandler

This figure shows the co-authorship network connecting the top 25 collaborators of Jason C. Chandler. A scholar is included among the top collaborators of Jason C. Chandler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason C. Chandler. Jason C. Chandler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donnellan, William B., Jesús G. Berdeja, Michael Byrne, et al.. (2024). Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).. Journal of Clinical Oncology. 42(16_suppl). e13575–e13575.

Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2021). Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. The Lancet Haematology. 8(4). e254–e266. 39 indexed citations

Hong, David S., Drew Rasco, Michael H. Veeder, et al.. (2019). A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 97(2). 102–111. 66 indexed citations

Waterhouse, David, Leora Horn, Craig H. Reynolds, et al.. (2018). Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. Cancer Chemotherapy and Pharmacology. 81(4). 679–686. 13 indexed citations

Spigel, David R., Craig H. Reynolds, David Waterhouse, et al.. (2018). Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370). Journal of Thoracic Oncology. 13(5). 682–688. 178 indexed citations

Giri, Smith, George Yaghmour, Jeremiah L. Deneve, et al.. (2017). Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality. Anticancer Research. 37(2). 813–818. 5 indexed citations

Gulley, James L., Arun Rajan, David R. Spigel, et al.. (2017). Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. The Lancet Oncology. 18(5). 599–610. 225 indexed citations

Spigel, David R., Lee S. Schwartzberg, David Waterhouse, et al.. (2017). P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153. Journal of Thoracic Oncology. 12(1). S1287–S1288. 39 indexed citations

Spigel, David R., Maen Hussein, David Waterhouse, et al.. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v461–v461. 76 indexed citations

10.

Kelly, Karen, J. R. Infante, Nicholas Iannotti, et al.. (2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Open Repository and Bibliography (University of Liège). 1 indexed citations

11.

Pandey, Manjari, George Yaghmour, Kruti Patel, et al.. (2016). Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Research and Treatment. 158(1). 195–202. 29 indexed citations

12.

Yaghmour, George, Omer Jamy, Rebecca Feldman, et al.. (2016). Genomic alterations in neuroendocrine cancers of the ovary. Journal of Ovarian Research. 9(1). 52–52. 11 indexed citations

13.

Blumenschein, George R., Jason C. Chandler, Edward B. Garon, et al.. (2016). PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S307–S307. 4 indexed citations

14.

Johnson, Benny, Smith Giri, Sara Nunnery, et al.. (2016). Comorbidities Drive Outcomes for Both Malignancy-Associated and Non–Malignancy-Associated Hemophagocytic Syndrome. Clinical Lymphoma Myeloma & Leukemia. 16(4). 230–236. 7 indexed citations

15.

Kelly, Karen, Manish R. Patel, Jeffrey R. Infante, et al.. (2016). Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial. Cancer Research. 76(14_Supplement). CT132–CT132. 1 indexed citations

16.

Chandler, Jason C., Ari M. Vanderwalde, Bradley G. Somer, Gregory A. Vidal, & Lee S. Schwartzberg. (2016). Analysis of 1261 metastatic cancer patients evaluated by comprehensive molecular profiling (CMP) including next-gen sequencing (NGS) from a single institution.. Journal of Clinical Oncology. 34(15_suppl). 11570–11570. 1 indexed citations

17.

Kelly, Karen, Manish R. Patel, Jeffrey R. Infante, et al.. (2015). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.. Journal of Clinical Oncology. 33(15_suppl). 3044–3044. 28 indexed citations

18.

Blum, William, Rebecca B. Klisovic, Heiko Becker, et al.. (2010). Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. Journal of Clinical Oncology. 28(33). 4919–4925. 71 indexed citations

19.

Kaste, Sue C., Robert F. Tamburro, Fredric A. Hoffer, et al.. (2006). Abdominal compartment syndrome in a newly diagnosed patient with Burkitt lymphoma. Pediatric Radiology. 36(3). 254–257. 5 indexed citations

20.

Samant, Sanjiv S., Wei Zheng, Nestor A. Parra, et al.. (2002). Verification of multileaf collimator leaf positions using an electronic portal imaging device. Medical Physics. 29(12). 2900–2912. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact